TG Therapeutics (TGTX) Stock Looks Reasonable On Earnings Yet Stretched After 386% Run
TG Therapeutics stock has delivered a very strong run over the past three years, yet the latest valuation checks still suggest the shares lean cheap rather than stretched. Recent excitement around Briumvi and a new Phase 2 trial has pulled more attention to the story, but the share price and the broader valuation signals are not fully aligned.
- Over the past three years TG Therapeutics has returned about 385.8% which puts a lot of pressure on today’s price to be supported by the underlying business.
- Progress with Briumvi and the start of a Phase 2 trial in treatment resistant schizophrenia can support expectations for future cash flows, while execution and clinical risk around these programs remains a key concern for what the stock is worth.
- The company screens as undervalued on most checks, with a value score of 5 out of 6, which means the broader set of indicators still leans in favor of the shares looking cheap rather than fully priced.
For investors, the debate is whether TG Therapeutics’ recent rally and news flow already reflect these positives or if the current valuation still leaves a meaningful margin of safety.
Is TG Therapeutics Still Cheap on Earnings?
The P/E multiple is a useful cross check for TG Therapeutics because the company now reports positive earnings that can be compared with its market value. On this measure, TG Therapeutics trades on about 16.0x earnings.
This sits below both the wider biotech industry average P/E of roughly 17.1x and the peer group average of about 23.3x. The fair P/E ratio implied by the model is about 23.9x, which is above the current level and indicates the stock trades at a discount to where it might sit given its size, margins and risk profile. Despite the interest around Briumvi and the new Phase 2 schizophrenia trial, the current P/E still prices TG Therapeutics below these tailored and industry benchmarks.
On the P/E multiple, TG Therapeutics stock currently appears undervalued compared with both its fair ratio and sector peers.
See what the numbers say about this price — find out in our valuation breakdown.
The TG Therapeutics Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where this valuation puzzle for TG Therapeutics leaves off. They spell out which assumptions about the company’s future growth, margins and earnings would need to hold for the stock to be worth materially more or less than today’s price, and they sit on Simply Wall St’s Community page. Each Narrative ties a fair value estimate to a specific mix of potential catalysts and risks so you can track which story is getting support over time.
The TG Therapeutics community is split between a subcutaneous Briumvi led upside story and a pricing and competition risk story that could cap returns.
Bull case: 37% undervalued
"Anticipated rapid payer mandates and consumer shifts could cause subcutaneous BRIUMVI to capture the majority of the 35-40% market segment extremely quickly, driving a step-change in total revenues and persistency…"
Read the full Bull Case to see why TG Therapeutics could be undervalued
Bear case: 160% overvalued
"The heavy reliance on BRIUMVI for revenue, combined with a narrow commercial portfolio and slow pipeline progression, leaves TG Therapeutics extremely exposed to competitive threats from established branded IV and newer subcutaneous options, which may lead to market share losses and declining top-line revenues as the anti-CD20 class matures…"
Read the full Bear Case to see why TG Therapeutics could be overvalued
Do you think there's more to the story for TG Therapeutics? Head over to our Community to see what others are saying!
The Bottom Line
For TG Therapeutics, the market multiple view still leans towards undervalued, even after a very strong three year move and active recent news flow. The high value score suggests the broader set of checks is consistent with that message rather than flagging an obviously stretched price.
From here, everything turns on whether Briumvi can deliver the scale and durability of revenue that the bullish narratives describe, without the competitive or execution setbacks highlighted in the bear case. The key question for investors is whether the current discount reflects an opportunity or whether the market is correctly pricing those concentrated product and pipeline risks.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com